



Case Study

Regeneus Cell Therapies

CASE STUDY





Next Generation Cell Therapies

PROF. EWA GOLDYS
DR. GUOZHEN LIU

On her first day at work a young CNBP researcher, Dr. Guozhen Liu sat in a meeting next to her supervisor Professor Ewa Goldys (Deputy Director, CNBP) and Australian entrepreneur and luminary, Dr. Graham Vesey.


Vesey's role is the Executive Director and Chief Scientific Officer of Regeneus Pty Ltd, a regenerative medicine company specializing in innovative cell-based therapies, targeting unmet medical needs in human and animal healthcare.

Little did Dr. Liu know that this was a turning point in her life, and that she, would be working closely with Regeneus in the coming years ahead - this based on her breakthrough cell labeling research, focused on the identification and selection of cells based on molecular secretions.



Fast forward two years and Dr. Liu's research inspired by this very first meeting, has given rise to a patented OnCELISA technology for selecting cell populations with specific biochemical characteristics and optimised therapeutic properties. The OnCELISA patent has been licenced to Regeneus Pty Ltd, who develop novel high added-value therapeutic products for the veterinary market, such as the Greencross (ASX:GXL) network of clinics.

These are set to be marketed directly by Regeneus, and in conjunction with a global marketing partner, a major veterinary pharmaceutical company Merial/Zoetis, and distributed through the global Henry Schein distribution network.



Joint work with Regeneus has been supported by a research contract at the end of which Dr. Liu and partners secured an ARC Linkage award. The Linkage research offers the tantalising prospect of developing a specific treatment for pain with outstanding effectiveness, both for animals, and, potentially for human health in the future as well. The approach of using secretions of tightly selected and recipient-matched cells is unique in the world and it will give Regeneus a critical edge to compete as part of the global economy.

Dr. Guozhen Liu and other CNBP scientists are part of the wave of early career researchers who will form a cradle of future innovative industries which will take Australia well into the 21st century. The products developed in this project will create a huge downstream market opportunity, which, for osteoarthritis amounts to 2,000,000 patients and for neuropathic pain, an additional 1,000,000 patients per year. It is no wonder that Dr. Liu looks confidently into the future, even more so, that she has now secured a highly coveted ARC Future Fellowship and major industry partners can't wait to hear about her latest work and results. ■